Akagera Medicines Receives $7.8 Million Grant Expansion to Advance Dendritic Cell-Targeted mRNA Tuberculosis Vaccine Toward First-in-Human Trial

Additional funding brings total funding commitment to $9.79 million and supports GMP manufacturing and IND-enabling toxicology for a Phase 1 clinical study WALTHAM, Mass., Nov. 18, 2026 /PRNewswire/ — Akagera Medicines, Inc., a clinical-stage biopharmaceutical company developing lipid…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks